Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Baxter
Harvard Business School
Moodys
McKesson

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Claims for Patent: 7,758,889

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,758,889
Title:Fullerenes in targeted therapies
Abstract: Herein we disclose a composition, comprising a C.sub.n-Ab, wherein C.sub.n is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is linked to the Cn. The composition can further comprise a therapeutic molecule associated with the C.sub.n-Ab. Also, we disclose a method of treating a disease in a mammal, comprising administering to the mammal an effective amount of the composition.
Inventor(s): Sagman; Uri (Toronto, CA), Rosenblum; Michael G. (Sugar Land, TX), Wilson; Lon J. (Houston, TX)
Assignee: Luna Innovations Incorporated (Roanoke, VA)
Application Number:10/623,110
Patent Claims:1. A composition, comprising: (i) a C.sub.n-Ab, wherein C.sub.n is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is covalently linked to the C.sub.n, wherein the antigen-binding site recognizes an antigen associated with a medical condition; and (ii) a pharmaceutically-acceptable carrier.

2. The composition of claim 1, wherein the C.sub.n is substituted with one or more water-solubilizing groups.

3. The composition of claim 1, wherein the Ab comprises an antigen-binding site selected from ZME-018, SCFVMEL, dSCFVMEL, GD2, HuM195, herceptin, BACH 250, ML 3-9, C 6.5, or .alpha.MMP9.

4. The composition of claim 1, further comprising a therapeutic molecule associated with the C.sub.n-Ab.

5. The composition of claim 4, wherein the therapeutic molecule is covalently bound to the C.sub.n.

6. The composition of claim 4, wherein the C.sub.n is substituted with a polar group and the therapeutic molecule is associated with the polar group.

7. The composition of claim 4, wherein the therapeutic molecule is paclitaxel, doxorubicin, vincristine, or cisplatin.

8. A method of treating a disease in a mammal, comprising: administering to the mammal an effective amount of a composition comprising (i) a C.sub.n-Ab, wherein C.sub.n is a fullerene or nanotube comprising n carbon atoms, and Ab is a moiety comprising an antigen-binding site and is covalently linked to the C.sub.n, wherein the antigen-binding site recognizes an antigen associated with the disease, and (ii) a pharmaceutically-acceptable carrier.

9. The method of claim 8, the C.sub.n is substituted with one or more water-solubilizing groups.

10. The method of claim 8, wherein the Ab comprises an antigen-binding site selected from ZME-018, SCFVMEL, dSCFVMEL, GD2, HuM195, herceptin, BACH 250, ML 3-9, C 6.5, or .alpha.MMP9.

11. The method of claim 8, wherein the disease is an oxidative stress disease.

12. The method of claim 8, wherein the composition is administered at a dosage of from about 0.001 mg C.sub.n per kg body weight per day to about 1 g C.sub.n per kg body weight per day.

13. The method of claim 8, wherein the composition further comprises a therapeutic molecule associated with the C.sub.n-Ab.

14. The method of claim 13, wherein the therapeutic molecule is paclitaxel, doxorubicin, vincristine, or cisplatin.

15. The method of claim 13, wherein the composition is administered at a dosage of from about 0.001 mg therapeutic molecule per kg body weight per day to about 1 g therapeutic molecule per kg body weight per day.

16. The method of claim 8, wherein the method further comprises administering an adjuvant to the mammal, wherein the adjuvant dissociates the therapeutic molecule from the C.sub.n-Ab.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Moodys
Medtronic
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.